UY26431A1 - Quimioterapia de combinación - Google Patents

Quimioterapia de combinación

Info

Publication number
UY26431A1
UY26431A1 UY26431A UY26431A UY26431A1 UY 26431 A1 UY26431 A1 UY 26431A1 UY 26431 A UY26431 A UY 26431A UY 26431 A UY26431 A UY 26431A UY 26431 A1 UY26431 A1 UY 26431A1
Authority
UY
Uruguay
Prior art keywords
combination chemotherapy
combination
chemotherapy
acetyldinaline
carboplatin
Prior art date
Application number
UY26431A
Other languages
English (en)
Inventor
Merriman Ronald Lynn
Klohs Wayne Daniel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY26431A1 publication Critical patent/UY26431A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La acetildinalina en combinación con paclitaxel y/o carboplatina es sinergística para tratar el cáncer.
UY26431A 1999-11-10 2000-11-09 Quimioterapia de combinación UY26431A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16488999P 1999-11-10 1999-11-10
US22256100P 2000-08-03 2000-08-03

Publications (1)

Publication Number Publication Date
UY26431A1 true UY26431A1 (es) 2000-12-29

Family

ID=26860956

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26431A UY26431A1 (es) 1999-11-10 2000-11-09 Quimioterapia de combinación

Country Status (17)

Country Link
EP (1) EP1229916A2 (es)
JP (1) JP2003513912A (es)
KR (1) KR20020060226A (es)
CN (1) CN1387438A (es)
AR (1) AR026400A1 (es)
AU (1) AU1583201A (es)
CA (1) CA2386876A1 (es)
GT (1) GT200000194A (es)
HU (1) HUP0203153A3 (es)
IL (1) IL149363A0 (es)
NZ (1) NZ518668A (es)
PA (1) PA8506201A1 (es)
PE (1) PE20011028A1 (es)
PL (1) PL355170A1 (es)
SV (1) SV2001000212A (es)
UY (1) UY26431A1 (es)
WO (1) WO2001034131A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US9115090B2 (en) 2003-12-02 2015-08-25 The Ohio State University Research Foundation Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
MX2007000610A (es) * 2004-07-16 2007-03-07 Pfizer Prod Inc Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
PL2415382T3 (pl) 2010-08-06 2013-02-28 Electrolux Home Products Corp Nv Zmywarka nablatowa
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases

Also Published As

Publication number Publication date
CA2386876A1 (en) 2001-05-17
CN1387438A (zh) 2002-12-25
AU1583201A (en) 2001-06-06
WO2001034131A2 (en) 2001-05-17
AR026400A1 (es) 2003-02-12
GT200000194A (es) 2002-05-03
IL149363A0 (en) 2002-11-10
HUP0203153A3 (en) 2005-01-28
EP1229916A2 (en) 2002-08-14
WO2001034131A3 (en) 2002-05-10
PE20011028A1 (es) 2001-10-12
HUP0203153A2 (hu) 2003-01-28
SV2001000212A (es) 2001-10-25
JP2003513912A (ja) 2003-04-15
PA8506201A1 (es) 2002-12-11
KR20020060226A (ko) 2002-07-16
NZ518668A (en) 2004-04-30
PL355170A1 (en) 2004-04-05

Similar Documents

Publication Publication Date Title
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
DE69708100T2 (de) Konjugate von cis-docosahexaensäure und paclitaxel
TR200100859T2 (tr) Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
UY26431A1 (es) Quimioterapia de combinación
AR044039A1 (es) Combinaciones antineoplasicas
BRPI0507463A (pt) uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine
HRPK20041072B3 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
DE60323529D1 (de) Rutheniumkomplexe mit antikrebswirkung
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
DE69905392D1 (de) Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid
TR200302193T4 (tr) Kombinasyon kemoterapisi.
AR029451A1 (es) Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia
ECSP003755A (es) Quimioterapia de combinacion
DOP2000000092A (es) Quimioterapia de combinación
PT938900E (pt) Profilaticos/medicamentos para estomatite
AR029958A1 (es) Uso de fosfato de estramustina en el tratamiento de metastasis osea y en el tratamiento de metastasis osea en pacientes con cancer de prostata
ES2196769T3 (es) Uso topico de loperamide para el tratamiento de infecciones microbianas.
IL148336A0 (en) Medicaments that contain xenogenic oligo-or/and polyribonucleotides
ECSP982458A (es) Aplicación oral de (+)-o- demetiltramadol como analgesico
UY29136A1 (es) Uso de epotilonas en el tratamiento de metastasis osea
AU300157S (en) Underwear
UY27923A1 (es) Combinaciones terapeuticas de inhibidores de quinas de erb b y terapias antineoplásicas
UA23977A (uk) Іhгібітор росту злоякісhих клітиh

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120529